These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34000449)

  • 1. Management of CLN1 Disease: International Clinical Consensus.
    Augustine EF; Adams HR; de Los Reyes E; Drago K; Frazier M; Guelbert N; Laine M; Levin T; Mink JW; Nickel M; Peifer D; Schulz A; Simonati A; Topcu M; Turunen JA; Williams R; Wirrell EC; King S
    Pediatr Neurol; 2021 Jul; 120():38-51. PubMed ID: 34000449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ppt1-deficiency dysregulates lysosomal Ca
    Mondal A; Appu AP; Sadhukhan T; Bagh MB; Previde RM; Sadhukhan S; Stojilkovic S; Liu A; Mukherjee AB
    J Inherit Metab Dis; 2022 May; 45(3):635-656. PubMed ID: 35150145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis.
    Fietz M; AlSayed M; Burke D; Cohen-Pfeffer J; Cooper JD; Dvořáková L; Giugliani R; Izzo E; Jahnová H; Lukacs Z; Mole SE; Noher de Halac I; Pearce DA; Poupetova H; Schulz A; Specchio N; Xin W; Miller N
    Mol Genet Metab; 2016 Sep; 119(1-2):160-7. PubMed ID: 27553878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuronal ceroid lipofuscinoses: research update.
    Wisniewski KE; Kida E; Connell F; Zhong N
    Neurol Sci; 2000; 21(3 Suppl):S49-56. PubMed ID: 11073228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis and therapies for infantile neuronal ceroid lipofuscinosis (infantile CLN1 disease).
    Hawkins-Salsbury JA; Cooper JD; Sands MS
    Biochim Biophys Acta; 2013 Nov; 1832(11):1906-9. PubMed ID: 23747979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of neuroinflammation and seizures in a mouse model of CLN1 batten disease using the small molecule enzyme mimetic, N-Tert-butyl hydroxylamine.
    Fyke Z; Johansson R; Scott AI; Wiley D; Chelsky D; Zak JD; Al Nakouzi N; Koster KP; Yoshii A
    Mol Genet Metab; 2024; 143(1-2):108537. PubMed ID: 39033629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cln3-mutations underlying juvenile neuronal ceroid lipofuscinosis cause significantly reduced levels of Palmitoyl-protein thioesterases-1 (Ppt1)-protein and Ppt1-enzyme activity in the lysosome.
    Appu AP; Bagh MB; Sadhukhan T; Mondal A; Casey S; Mukherjee AB
    J Inherit Metab Dis; 2019 Sep; 42(5):944-954. PubMed ID: 31025705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrathecal enzyme replacement therapy improves motor function and survival in a preclinical mouse model of infantile neuronal ceroid lipofuscinosis.
    Lu JY; Nelvagal HR; Wang L; Birnbaum SG; Cooper JD; Hofmann SL
    Mol Genet Metab; 2015; 116(1-2):98-105. PubMed ID: 25982063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Juvenile-onset neuronal ceroid lipofuscinosis with infantile CLN1 mutation and palmitoyl-protein thioesterase deficiency.
    Kälviäinen R; Eriksson K; Losekoot M; Sorri I; Harvima I; Santavuori P; Järvelä I; Autti T; Vanninen R; Salmenperä T; van Diggelen OP
    Eur J Neurol; 2007 Apr; 14(4):369-72. PubMed ID: 17388982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of lysosomal nutrient sensing scaffold contributes to pathogenesis of a fatal neurodegenerative lysosomal storage disease.
    Bagh MB; Appu AP; Sadhukhan T; Mondal A; Plavelil N; Raghavankutty M; Supran AM; Sadhukhan S; Liu A; Mukherjee AB
    J Biol Chem; 2024 Feb; 300(2):105641. PubMed ID: 38211816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management Strategies for CLN2 Disease.
    Williams RE; Adams HR; Blohm M; Cohen-Pfeffer JL; de Los Reyes E; Denecke J; Drago K; Fairhurst C; Frazier M; Guelbert N; Kiss S; Kofler A; Lawson JA; Lehwald L; Leung MA; Mikhaylova S; Mink JW; Nickel M; Shediac R; Sims K; Specchio N; Topcu M; von Löbbecke I; West A; Zernikow B; Schulz A
    Pediatr Neurol; 2017 Apr; 69():102-112. PubMed ID: 28335910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel c.776_777insA mutation in CLN1 leads to infantile neuronal ceroid lipofuscinosis.
    Miller JN; Pearce DA
    J Child Neurol; 2013 Sep; 28(9):1106-11. PubMed ID: 23857568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variant late infantile neuronal ceroid lipofuscinosis because of CLN1 mutations.
    Simonati A; Tessa A; Bernardina BD; Biancheri R; Veneselli E; Tozzi G; Bonsignore M; Grosso S; Piemonte F; Santorelli FM
    Pediatr Neurol; 2009 Apr; 40(4):271-6. PubMed ID: 19302939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral cysteamine bitartrate and N-acetylcysteine for patients with infantile neuronal ceroid lipofuscinosis: a pilot study.
    Levin SW; Baker EH; Zein WM; Zhang Z; Quezado ZM; Miao N; Gropman A; Griffin KJ; Bianconi S; Chandra G; Khan OI; Caruso RC; Liu A; Mukherjee AB
    Lancet Neurol; 2014 Aug; 13(8):777-87. PubMed ID: 24997880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre- and postnatal diagnosis of patients with CLN1 and CLN2 by assay of palmitoyl-protein thioesterase and tripeptidyl-peptidase I activities.
    Young EP; Worthington VC; Jackson M; Winchester BG
    Eur J Paediatr Neurol; 2001; 5 Suppl A():193-6. PubMed ID: 11588996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuronal ceroid lipofuscinoses caused by defects in soluble lysosomal enzymes (CLN1 and CLN2).
    Hofmann SL; Atashband A; Cho SK; Das AK; Gupta P; Lu JY
    Curr Mol Med; 2002 Aug; 2(5):423-37. PubMed ID: 12125808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic effects of treating the spinal cord and brain in CLN1 disease.
    Shyng C; Nelvagal HR; Dearborn JT; Tyynelä J; Schmidt RE; Sands MS; Cooper JD
    Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5920-E5929. PubMed ID: 28673981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive functional characterization of murine infantile Batten disease including Parkinson-like behavior and dopaminergic markers.
    Dearborn JT; Harmon SK; Fowler SC; O'Malley KL; Taylor GT; Sands MS; Wozniak DF
    Sci Rep; 2015 Aug; 5():12752. PubMed ID: 26238334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The neuronal ceroid-lipofuscinoses.
    Bennett MJ; Rakheja D
    Dev Disabil Res Rev; 2013; 17(3):254-9. PubMed ID: 23798013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients.
    Mole SE; Schulz A; Badoe E; Berkovic SF; de Los Reyes EC; Dulz S; Gissen P; Guelbert N; Lourenco CM; Mason HL; Mink JW; Murphy N; Nickel M; Olaya JE; Scarpa M; Scheffer IE; Simonati A; Specchio N; Von Löbbecke I; Wang RY; Williams RE
    Orphanet J Rare Dis; 2021 Apr; 16(1):185. PubMed ID: 33882967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.